80% of men survive NHL (all subtypes combined) for at least one year, and this is predicted to fall to 68% surviving for five years or more, as shown by
Non-Hodgkin Lymphoma (C82-C85), Age-Standardised One-, Five- and Ten-Year Net Survival, Adults (Aged 15-99), England and Wales, 2010-2011
|1-Year Survival (%)||5-Year Survival (%)||10-Year Survival (%)|
95% LCL and 95% UCL are the 95% lower and upper
Five- and ten-year survival is predicted using an excess hazard statistical model
NHL survival continues to fall beyond five years after diagnosis. 62% of men and 64% of women are predicted to survive their disease for ten years or more, as shown by age-standardised net survival for patients diagnosed with NHL during 2010-2011 in England and Wales. Out of 20 common cancers in England and Wales, ten-year survival for NHL ranks 7th highest overall.
Non-Hodgkin Lymphoma (C82-C85), Net Survival up to Ten Years after Diagnosis, Adults (Aged 15-99), England and Wales, 2010-2011
Survival for NHL is reported in Scotland and Northern Ireland,[2,3] though it is difficult to make survival comparisons between countries due to different methodologies and criteria for including patients in analyses.
Survival varies considerably by NHL subtype. One-year relative survival is significantly better for follicular lymphoma (96%) than for diffuse large B-cell lymphoma (65%), mantle cell lymphoma (71%) or marginal zone lymphoma (92%) for patients diagnosed during 2004-2011 in the Haematological Malignancy Research Network (HMRN) region. Five-year survival follows a similar pattern and is significantly higher for follicular lymphoma (87%) and significantly lower for mantle cell lymphoma (27%) in comparison with the two other main NHL subtypes. Mantle cell lymphoma, which is an aggressive NHL subtype, shows the largest decrease in survival between one and five years after diagnosis.
Non-Hodgkin Lymphoma, Main Subtypes, One- and Five-Year Relative Survival, All Ages, HMRN, 2004-2011
In this section, survival by subtype is provided for the HMRN region in the north-east of England.
About this data
Data is for: England and Wales (2010-2011), ICD-10 C82-85. HMRN (2004-2011), main subtypes.
NHL statistics by subtype are provided for the Haematological Malignancy Research Network (HMRN) region. HMRN covers a population of 3.6 million and is set within the former adjacent UK Cancer Networks of Yorkshire and the Humber & Yorkshire Coast England. While HMRN may not be fully representative of the country as a whole due to variation in local healthcare provision standards and policies, the population does have a similar socio-demographic profile to the UK.